Repotrectinib and Orforglipron: Interaction Details

Brand names
Repotrectinib
Augtyro
Orforglipron
Foundayo
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

What Happens When You Take Repotrectinib With Orforglipron

What can happen when they are taken together (rated Major)

Reduced orforglipron exposure and reduced of orforglipron

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Giving orforglipron together with moderate can lower orforglipron exposure, and this may diminish how well orforglipron works. Efavirenz, a moderate CYP3A4 , was evaluated at 600 mg twice daily using physiologically based modeling (a simulation rather than a clinical measurement) in drug interaction studies.

In that modeling, with efavirenz decreased the orforglipron by 61% and the by 33%. When orforglipron is used with moderate CYP3A4 inducers, effectiveness should be monitored and the dosage increased as needed.1

The Repotrectinib and Orforglipron Interaction, Explained

Repotrectinib (Augtyro) may make orforglipron (Foundayo) work less well. Repotrectinib can speed up an enzyme in your body () that breaks down orforglipron. That means less of the medicine stays in your blood, so it may not control your blood sugar or weight as well as expected.

This is based on computer modeling with a similar enzyme-speeding drug, not on studies of these two medicines together. Please keep taking both as prescribed. Your pharmacist or doctor can watch how well orforglipron is working and may adjust your dose to fit your needs.

Mechanism: Repotrectinib is a (moderate), which may increase CYP3A4-mediated of orforglipron and lower its exposure.

  • Magnitude (simulated): PBPK modeling with efavirenz 600 mg twice daily, a moderate CYP3A4 inducer, reduced orforglipron by 61% and by 33%.
  • Evidence: Theoretical (modeling-based); no direct clinical study with repotrectinib. Onset unspecified.
  • Management: Monitor orforglipron effectiveness (e.g., glycemic or weight response) and escalate the dose as needed while coadministered. Reassess if repotrectinib is stopped, since exposure may rise again.

See the 1 reference behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Repotrectinib and Orforglipron Interact

The likely mechanism

of -mediated of orforglipron

In short: Repotrectinib speeds up CYP3A4, an enzyme that breaks down orforglipron, so orforglipron can be cleared faster.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When One Drug Lowers Another’s Level”, one chapter of our one-minute explainer. See how it works 

How to Manage the Repotrectinib and Orforglipron Interaction

Your care team can manage this by checking how well orforglipron is working and adjusting the dose as needed.

  • Keep taking both medicines as prescribed. Do not change or stop either one on your own.
  • Your team may monitor your response to orforglipron more closely and may increase the dose if needed.
  • Tell your pharmacist or prescriber if you notice your blood sugar or weight response getting worse.
  • Let them know if repotrectinib is started, changed, or stopped, since your orforglipron dose may need to be reviewed again.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Repotrectinib or Orforglipron need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: FOUNDAYO oral tablet, orforglipron oral tablet

    In drug interaction studies, physiologically based modeling was used to simulate the of orforglipron with efavirenz (a moderate ) at 600 mg twice daily. The simulation showed a 61% reduction in orforglipron and a 33% reduction in .1

Repotrectinib and Orforglipron: Common Questions

How serious is the Repotrectinib and Orforglipron interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Repotrectinib and Orforglipron interaction managed?

Your care team can manage this by checking how well orforglipron is working and adjusting the dose as needed. Keep taking both medicines as prescribed. Do not change or stop either one on your own. Your team may monitor your response to orforglipron more closely and may increase the dose if needed. Tell your pharmacist or prescriber if you notice your blood sugar or weight response getting worse.… Management is individual — always follow your own care team's guidance.

Does taking Repotrectinib and Orforglipron at different times of day help?

No. Taking them at different times of day does not prevent this one. Repotrectinib speeds up , an enzyme that breaks down orforglipron, so orforglipron can be cleared faster. That change lasts while repotrectinib is being taken and can continue for a while after the last dose.

Your pharmacist or prescriber can tell you how they will manage it.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Repotrectinib and Orforglipron Interaction

Ask in your own words about taking Repotrectinib and Orforglipron together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (1)

  1. Product Information: FOUNDAYO™ oral tablet, orforglipron oral tablet. Lilly USA LLC, Indianapolis, IN, 2026. DailyMed
Was this write-up helpful?

Other Serious Interactions of Repotrectinib and Orforglipron

Also serious with Repotrectinib

Also serious with Orforglipron

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Repotrectinib

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.